BiotechTube

Elestat + Pataday

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Allergic Conjunctivitis

Conditions

Allergic Conjunctivitis

Trial Timeline

Oct 1, 2007 → —

NCT ID
NCT00534794

About Elestat + Pataday

Elestat + Pataday is a approved stage product being developed by Merck for Allergic Conjunctivitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00534794. Target conditions include Allergic Conjunctivitis.

What happened to similar drugs?

20 of 20 similar drugs in Allergic Conjunctivitis were approved

Approved (20) Terminated (3) Active (0)
✅placebo, isotonic ciclesonide, hypotonic ciclesonideSumitomo PharmaApproved
✅ciclesonide nasal aerosol + ciclesonide nasal spraySumitomo PharmaApproved
✅Cetirizine + LoratadineJohnson & JohnsonApproved
✅Budesonide + PlaceboAstraZenecaApproved
✅Ciclesonide nasal spray + placebo Azelastine + Ciclesonide nasal spray + AzelastineAstraZenecaApproved
✅epinastine HCL and olopatadine HCLMerckApproved
✅Placebo + Montelukast + Fluticasone propionateMerckApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00534794ApprovedCompleted

Competing Products

20 competing products in Allergic Conjunctivitis

See all competitors
ProductCompanyStageHype Score
BriquilimabJasper TherapeuticsPhase 1
11
LY3650150 + Placebo + Standard therapy for INCSEli LillyPhase 3
47
Lesigercept + PlaceboYuhanPhase 2
42
YH35324 + Omalizumab + PlaceboYuhanPhase 1
29
Bilastine + Desloratadine + PlaceboYuhanPhase 3
40
ASP2390 + PlaceboAstellas PharmaPhase 1
33
ASP4070 + PlaceboAstellas PharmaPhase 2
35
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placeboShionogiPhase 2
35
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + PlaceboOno PharmaceuticalPhase 2
35
Prednisolone + VoriconazoleCiplaPhase 2/3
38
placebo, isotonic ciclesonide, hypotonic ciclesonideSumitomo PharmaApproved
35
ciclesonide nasal aerosol + ciclesonide nasal spraySumitomo PharmaApproved
43
ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalationSumitomo PharmaPhase 3
40
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
40
ciclesonide nasal aerosol + mometasone Aqueous (AQ) nasal spraySumitomo PharmaPhase 1
29
ciclesonide + mometasoneSumitomo PharmaPhase 3
40
DSP-3025 + PlaceboSumitomo PharmaPhase 1
29
ciclesonide nasal aerosol + PlaceboSumitomo PharmaPhase 3
40
Ciclesonide HFA 80 mcg + Ciclesonide HFA 160 mcg + PlaceboSumitomo PharmaPhase 3
40
Ciclesonide HFA Nasal Aerosol 320 mcg + Ciclesonide HFA Nasal Aerosol 160 mcg + HFA Nasal Aerosol placebo + Ciclesonide Aqueous Nasal Spray 200 mcg + AQ Nasal Spray Placebo + Placebo plus Dexamethasone HFA + Placebo AQ plus Dexamethasone 6 mgSumitomo PharmaPhase 3
40